A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Study Status

Open to Enrollment

Study Description

TG02 citrate (study drug) is an investigational drug being tested and is not approved for sale in the US by the FDA. The purpose of this research study is to find out what effects (good and bad) TG02 citrate has on you and your cancer (relapsed acute leukemia, high risk myelodysplasia, relapsed chronic myelogenous leukemia in blast crisis, or relapsed multiple myeloma). The study doctor will give TG02 citrate to people in this study to find the highest dose of TG02 citrate that people can tolerate. Another purpose of this study is to find out if TG02 citrate is safe, tolerable and effective for people with the above conditions.

TG02 has shown anti-tumor activity in laboratory tests and animal studies. The way that TG02 citrate causes anti-tumor activity is not fully known, but researchers believe that TG02 citrate may affect tumors by slowing or stopping the growth of tumor cells in the body.

Disease Status and/or Stage

Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or High-risk Myelodysplasia (MDS)

Sponsor

Tragara Pharmaceuticals

Key Eligibility

  • Men and women age 18 and over
  • Diagnosis of:
    • Acute Myelogenous Leukemia (AML)
    • Acute Lymphoblastic Leukemia (ALL)
    • Chronic Myelogenous Leukemia currently in blast crisis (defined as ≥ 30% blasts in bone marrow) or
    • Myelodysplastic Syndrome (MDS)
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Gail Roboz, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
roh2026@med.cornell.edu

Top of page